Abbott to spin off $8.5B Nutrition business via tax-free distribution by end of 2027

ABBOTT LABORATORIES

Nutrition spin-off will hold Similac, PediaSure, Pedialyte, Glucerna and Ensure, with ~$8.5B annual sales, ~16,000 employees and 14 manufacturing sites.
Remaining Abbott will have ~$42B in sales and ~106,000 employees, focused on medical devices, biowearables, diagnostics and established medicines.
Separation structured as a tax-free distribution to Abbott shareholders; combined Abbott and Nutrition dividends expected to equal Abbott's current payout.
Daniel Salvadori, EVP and group president of Established Pharmaceuticals and Nutritional Products, will become CEO of the new Nutrition company.
Abbott reaffirmed 2026 guidance and said 2027 guidance, due in January, is unaffected; one-time transaction charges to be quantified later.

Featured in Daily 8-K Digest

Selected #4 for 2026-10-21. Read digest

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.